{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:05:15Z","timestamp":1784253915209,"version":"3.55.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"SHODH - ScHeme of Developing High Quality Research, Education Department, Government of Gujarat, India","award":["KCG\/SHODH\/2022-23\/ 2021013712"],"award-info":[{"award-number":["KCG\/SHODH\/2022-23\/ 2021013712"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-03166-6","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T11:33:50Z","timestamp":1765366430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The evolving landscape of cancer cachexia prevention: A review of metronomic chemotherapy and drug repurposing strategies"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4824-7673","authenticated-orcid":false,"given":"Anshu","family":"Thakur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3724-0986","authenticated-orcid":false,"given":"Mehul R.","family":"Chorawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"3166_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/601434","volume":"2011","author":"CL Donohoe","year":"2011","unstructured":"Donohoe CL, Ryan AM, Reynolds JV. Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract. 2011;2011:1\u201313. https:\/\/doi.org\/10.1155\/2011\/601434.","journal-title":"Gastroenterol Res Pract"},{"key":"3166_CR2","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.2147\/CMAR.S261585","volume":"12","author":"J Ni","year":"2020","unstructured":"Ni J, Zhang L. Cancer cachexia: definition, staging, and emerging treatments. Cancer Manag Res. 2020;12:5597\u2013605. https:\/\/doi.org\/10.2147\/CMAR.S261585.","journal-title":"Cancer Manag Res"},{"key":"3166_CR3","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v7.i4.17","volume":"7","author":"T Aoyagi","year":"2015","unstructured":"Aoyagi T, Terracina KP, Raza A, Matsubara H, Takabe K. Cancer cachexia, mechanism and treatment. World J Gastrointest Oncol. 2015;7:17. https:\/\/doi.org\/10.4251\/wjgo.v7.i4.17.","journal-title":"World J Gastrointest Oncol"},{"issue":"2","key":"3166_CR4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s13539-012-0087-1","volume":"4","author":"VC Vaughan","year":"2013","unstructured":"Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle. 2013;4(2):95\u2013109. https:\/\/doi.org\/10.1007\/s13539-012-0087-1.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3166_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41416-022-01826-2","volume":"127","author":"J McGovern","year":"2022","unstructured":"McGovern J, Dolan RD, Skipworth RJ, Laird BJ, McMillan DC. Cancer cachexia: a nutritional or a systemic inflammatory syndrome? Br J Cancer. 2022;127:379\u201382. https:\/\/doi.org\/10.1038\/s41416-022-01826-2.","journal-title":"Br J Cancer"},{"key":"3166_CR6","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1038\/s42255-024-01167-9","volume":"6","author":"M Berriel Diaz","year":"2024","unstructured":"Berriel Diaz M, Rohm M, Herzig S. Cancer cachexia: multilevel metabolic dysfunction. Nat Metab. 2024;6:2222\u201345. https:\/\/doi.org\/10.1038\/s42255-024-01167-9.","journal-title":"Nat Metab"},{"key":"3166_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans WJ, Morley JE, Argil\u00e9s J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008;27:793\u20139. https:\/\/doi.org\/10.1016\/j.clnu.2008.06.013.","journal-title":"Clin Nutr"},{"issue":"5","key":"3166_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","journal-title":"Lancet Oncol"},{"key":"3166_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clnu.2018.08.002","volume":"38","author":"T Cederholm","year":"2019","unstructured":"Cederholm T, Jensen GL, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GLIM criteria for the diagnosis of malnutrition \u2013 a consensus report from the global clinical nutrition community. Clin Nutr. 2019;38:1\u20139. https:\/\/doi.org\/10.1016\/j.clnu.2018.08.002.","journal-title":"Clin Nutr"},{"key":"3166_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1017\/S0029665108007131","volume":"67","author":"DC McMillan","year":"2008","unstructured":"McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer: Nutrition Society and BAPEN Medical Symposium on \u2018Nutrition support in cancer therapy.\u2019 Proc Nutr Soc. 2008;67:257\u201362. https:\/\/doi.org\/10.1017\/S0029665108007131.","journal-title":"Proc Nutr Soc"},{"key":"3166_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41571-023-00734-5","volume":"20","author":"JM Argil\u00e9s","year":"2023","unstructured":"Argil\u00e9s JM, L\u00f3pez-Soriano FJ, Stemmler B, Busquets S. Cancer-associated cachexia \u2014 understanding the tumour macroenvironment and microenvironment to improve management. Nat Rev Clin Oncol. 2023;20:250\u201364. https:\/\/doi.org\/10.1038\/s41571-023-00734-5.","journal-title":"Nat Rev Clin Oncol"},{"key":"3166_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01454-0","volume":"16","author":"T Setiawan","year":"2023","unstructured":"Setiawan T, Sari IN, Wijaya YT, Julianto NM, Muhammad JA, Lee H, et al. Cancer cachexia: molecular mechanisms and treatment strategies. J Hematol Oncol. 2023;16:54. https:\/\/doi.org\/10.1186\/s13045-023-01454-0.","journal-title":"J Hematol Oncol"},{"key":"3166_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072321","volume":"21","author":"GWPD Fonseca","year":"2020","unstructured":"Fonseca GWPD, Farkas J, Dora E, Von Haehling S, Lainscak M. Cancer cachexia and related metabolic dysfunction. Int J Mol Sci. 2020;21:2321. https:\/\/doi.org\/10.3390\/ijms21072321.","journal-title":"Int J Mol Sci"},{"key":"3166_CR14","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/jcsm.12232","volume":"8","author":"JL Brown","year":"2017","unstructured":"Brown JL, Rosa-Caldwell ME, Lee DE, Blackwell TA, Brown LA, Perry RA, et al. Mitochondrial degeneration precedes the development of muscle atrophy in progression of cancer cachexia in tumour\u2010bearing mice. J Cachexia Sarcopenia Muscle. 2017;8:926\u201338. https:\/\/doi.org\/10.1002\/jcsm.12232.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3166_CR15","doi-asserted-by":"publisher","first-page":"R201","DOI":"10.1152\/ajpregu.00300.2010","volume":"300","author":"JP White","year":"2011","unstructured":"White JP, Baltgalvis KA, Puppa MJ, Sato S, Baynes JW, Carson JA. Muscle oxidative capacity during IL-6-dependent cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2011;300:R201-11. https:\/\/doi.org\/10.1152\/ajpregu.00300.2010.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"3166_CR16","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1096\/fj.201801862R","volume":"33","author":"R Ballar\u00f2","year":"2019","unstructured":"Ballar\u00f2 R, Beltr\u00e0 M, De Lucia S, Pin F, Ranjbar K, Hulmi JJ, et al. Moderate exercise in mice improves cancer plus chemotherapy-induced muscle wasting and mitochondrial alterations. FASEB J. 2019;33:5482\u201394. https:\/\/doi.org\/10.1096\/fj.201801862R.","journal-title":"FASEB J"},{"key":"3166_CR17","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1158\/1078-0432.CCR-04-2626","volume":"11","author":"GJ Kelloff","year":"2005","unstructured":"Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785\u2013808. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2626.","journal-title":"Clin Cancer Res"},{"key":"3166_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/619649","volume":"2014","author":"D Diakowska","year":"2014","unstructured":"Diakowska D, Markocka-M\u0105czka K, Szelachowski P, Grabowski K. Serum levels of resistin, adiponectin, and apelin in gastroesophageal cancer patients. Dis Markers. 2014;2014:1\u20138. https:\/\/doi.org\/10.1155\/2014\/619649.","journal-title":"Dis Markers"},{"issue":"11","key":"3166_CR19","doi-asserted-by":"publisher","first-page":"5531","DOI":"10.1158\/0008-5472.CAN-06-4585","volume":"67","author":"T Agustsson","year":"2007","unstructured":"Agustsson T, Ryd\u00e9n M, Hoffstedt J, Van Harmelen V, Dicker A, Laurencikiene J, et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007;67(11):5531\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4585.","journal-title":"Cancer Res"},{"key":"3166_CR20","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121221","volume":"3","author":"GK Arora","year":"2018","unstructured":"Arora GK, Gupta A, Narayanan S, Guo T, Iyengar P, Infante RE. Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin. JCI Insight. 2018;3:e121221. https:\/\/doi.org\/10.1172\/jci.insight.121221.","journal-title":"JCI Insight"},{"key":"3166_CR21","doi-asserted-by":"publisher","first-page":"32178","DOI":"10.1074\/jbc.M114.601096","volume":"289","author":"W Zhang","year":"2014","unstructured":"Zhang W, Mottillo EP, Zhao J, Gartung A, VanHecke GC, Lee J-F, et al. Adipocyte lipolysis-stimulated interleukin-6 production requires sphingosine kinase 1 activity. J Biol Chem. 2014;289:32178\u201385. https:\/\/doi.org\/10.1074\/jbc.M114.601096.","journal-title":"J Biol Chem"},{"key":"3166_CR22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131870","volume":"5","author":"C Laurens","year":"2020","unstructured":"Laurens C, Parmar A, Murphy E, Carper D, Lair B, Maes P, et al. Growth and differentiation factor 15 is secreted by skeletal muscle during exercise and promotes lipolysis in humans. JCI Insight. 2020;5:e131870. https:\/\/doi.org\/10.1172\/jci.insight.131870.","journal-title":"JCI Insight"},{"key":"3166_CR23","doi-asserted-by":"publisher","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","volume":"303","author":"A Bonetto","year":"2012","unstructured":"Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, et al. JAK\/STAT3 pathway Inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol-Endocrinol Metab 2012;303:E410-21. https:\/\/doi.org\/10.1152\/ajpendo.00039.2012.","journal-title":"Am J Physiol-Endocrinol Metab\u00a0"},{"issue":"5","key":"3166_CR24","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1172\/JCI115767","volume":"89","author":"G Strassmann","year":"1992","unstructured":"Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992;89(5):1681\u20134. https:\/\/doi.org\/10.1172\/JCI115767.","journal-title":"J Clin Invest"},{"issue":"1","key":"3166_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/jcsm.13109","volume":"14","author":"I Pototschnig","year":"2023","unstructured":"Pototschnig I, Feiler U, Diwoky C, Vesely PW, Rauchenwald T, Paar M, et al. Interleukin-6 initiates muscle\u2010 and adipose tissue wasting in a novel C57BL\/6 model of cancer\u2010associated cachexia. J Cachexia Sarcopenia Muscle. 2023;14(1):93\u2013107. https:\/\/doi.org\/10.1002\/jcsm.13109.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3166_CR26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190450","volume":"218","author":"JE Rupert","year":"2021","unstructured":"Rupert JE, Narasimhan A, Jengelley DHA, Jiang Y, Liu J, Au E, et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J Exp Med. 2021;218:e20190450. https:\/\/doi.org\/10.1084\/jem.20190450.","journal-title":"J Exp Med"},{"key":"3166_CR27","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/320584a0","volume":"320","author":"B Beutler","year":"1986","unstructured":"Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature. 1986;320:584\u20138. https:\/\/doi.org\/10.1038\/320584a0.","journal-title":"Nature"},{"key":"3166_CR28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/0092-8674(93)90243-J","volume":"73","author":"BM Spiegelman","year":"1993","unstructured":"Spiegelman BM, Hotamisligil GS. Through thick and thin: wasting, obesity, and TNF\u03b1. Cell. 1993;73:625\u20137. https:\/\/doi.org\/10.1016\/0092-8674(93)90243-J.","journal-title":"Cell"},{"issue":"5","key":"3166_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361\u201371. https:\/\/doi.org\/10.1038\/nrc2628.","journal-title":"Nat Rev Cancer"},{"key":"3166_CR30","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nature24042","volume":"550","author":"J-Y Hsu","year":"2017","unstructured":"Hsu J-Y, Crawley S, Chen M, Ayupova DA, Lindhout DA, Higbee J, et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature. 2017;550:255\u20139. https:\/\/doi.org\/10.1038\/nature24042.","journal-title":"Nature"},{"key":"3166_CR31","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/nm1677","volume":"13","author":"H Johnen","year":"2007","unstructured":"Johnen H, Lin S, Kuffner T, Brown DA, Tsai VW-W, Bauskin AR, et al. Tumor-induced anorexia and weight loss are mediated by the TGF-\u03b2 superfamily cytokine MIC-1. Nat Med. 2007;13:1333\u201340. https:\/\/doi.org\/10.1038\/nm1677.","journal-title":"Nat Med"},{"key":"3166_CR32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2106868118","volume":"118","author":"I Cimino","year":"2021","unstructured":"Cimino I, Kim H, Tung YCL, Pedersen K, Rimmington D, Tadross JA, et al. Activation of the hypothalamic\u2013pituitary\u2013adrenal axis by exogenous and endogenous GDF15. Proc Natl Acad Sci U S A. 2021;118:e2106868118. https:\/\/doi.org\/10.1073\/pnas.2106868118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"3166_CR33","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1242\/dev.117598","volume":"142","author":"K Onishi","year":"2015","unstructured":"Onishi K, Zandstra PW. LIF signaling in stem cells and development. Development. 2015;142(13):2230\u20136. https:\/\/doi.org\/10.1242\/dev.117598.","journal-title":"Development"},{"key":"3166_CR34","doi-asserted-by":"publisher","first-page":"19976","DOI":"10.1074\/jbc.M115.638411","volume":"290","author":"DN Seto","year":"2015","unstructured":"Seto DN, Kandarian SC, Jackman RW. A key role for leukemia inhibitory factor in C26 cancer cachexia. J Biol Chem. 2015;290:19976\u201386. https:\/\/doi.org\/10.1074\/jbc.M115.638411.","journal-title":"J Biol Chem"},{"key":"3166_CR35","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/jcsm.12346","volume":"9","author":"SC Kandarian","year":"2018","unstructured":"Kandarian SC, Nosacka RL, Delitto AE, Judge AR, Judge SM, Ganey JD, et al. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour\u2010bearing mice. J Cachexia Sarcopenia Muscle. 2018;9:1109\u201320. https:\/\/doi.org\/10.1002\/jcsm.12346.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3166_CR36","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.annonc.2021.08.1748","volume":"32","author":"Y Loriot","year":"2021","unstructured":"Loriot Y, Marabelle A, Gu\u00e9gan JP, Danlos FX, Besse B, Chaput N, et al. Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Ann Oncol. 2021;32:1381\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1748.","journal-title":"Ann Oncol"},{"issue":"5","key":"3166_CR37","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","volume":"24","author":"TR Flint","year":"2016","unstructured":"Flint TR, Janowitz T, Connell CM, Roberts EW, Denton AE, Coll AP, et al. Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity. Cell Metab. 2016;24(5):672\u201384. https:\/\/doi.org\/10.1016\/j.cmet.2016.10.010.","journal-title":"Cell Metab"},{"issue":"2","key":"3166_CR38","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1210\/en.2009-0865","volume":"151","author":"AP Arruda","year":"2010","unstructured":"Arruda AP, Milanski M, Romanatto T, Solon C, Coope A, Alberici LC, et al. Hypothalamic actions of tumor necrosis factor \u03b1 provide the thermogenic core for the wastage syndrome in cachexia. Endocrinology. 2010;151(2):683\u201394. https:\/\/doi.org\/10.1210\/en.2009-0865.","journal-title":"Endocrinology"},{"issue":"1","key":"3166_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22361-3","volume":"12","author":"B Olson","year":"2021","unstructured":"Olson B, Zhu X, Norgard MA, Levasseur PR, Butler JT, Buenafe A, et al. Lipocalin 2 mediates appetite suppression during pancreatic cancer cachexia. Nat Commun. 2021;12(1):2057. https:\/\/doi.org\/10.1038\/s41467-021-22361-3.","journal-title":"Nat Commun"},{"issue":"2","key":"3166_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.peptides.2004.01.012","volume":"25","author":"MM Meguid","year":"2004","unstructured":"Meguid MM, Ramos EJB, Laviano A, Varma M, Sato T, Chen C, et al. Tumor anorexia: effects on neuropeptide Y and monoamines in paraventricular nucleus. Peptides. 2004;25(2):261\u20136. https:\/\/doi.org\/10.1016\/j.peptides.2004.01.012.","journal-title":"Peptides"},{"key":"3166_CR41","first-page":"3949","volume":"29","author":"I Legakis","year":"2009","unstructured":"Legakis I, Stathopoulos J, Matzouridis T, Stathopoulos GP. Decreased plasma ghrelin levels in patients with advanced cancer and weight loss in comparison to healthy individuals. Anticancer Res. 2009;29:3949\u201352.","journal-title":"Anticancer Res"},{"key":"3166_CR42","doi-asserted-by":"publisher","unstructured":"Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014;5:186\u201392. Sage Publications.\u00a0https:\/\/doi.org\/10.4103\/0976-500x.136098.","DOI":"10.4103\/0976-500x.136098"},{"key":"3166_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092471","volume":"15","author":"E Muraro","year":"2023","unstructured":"Muraro E, Vinante L, Fratta E, Bearz A, H\u00f6fler D, Steffan A, et al. Metronomic chemotherapy: anti-tumor pathways and combination with immune checkpoint inhibitors. Cancers. 2023;15:2471. https:\/\/doi.org\/10.3390\/cancers15092471.","journal-title":"Cancers"},{"key":"3166_CR44","doi-asserted-by":"publisher","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","volume":"105","author":"MEC Lutsiak","year":"2005","unstructured":"Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H. <article-title update=\"added\">Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862\u20138. https:\/\/doi.org\/10.1182\/blood-2004-06-2410.","journal-title":"Blood"},{"key":"3166_CR45","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1002\/ijc.32803","volume":"147","author":"C Laheurte","year":"2020","unstructured":"Laheurte C, Thiery-Vuillemin A, Calcagno F, Legros A, Simonin H, Boullerot L, et al. Metronomic cyclophosphamide induces regulatory T cells depletion and PSA\u2010specific T cells reactivation in patients with biochemical recurrent prostate cancer. Int J Cancer. 2020;147:1199\u2013205. https:\/\/doi.org\/10.1002\/ijc.32803.","journal-title":"Int J Cancer"},{"key":"3166_CR46","doi-asserted-by":"publisher","first-page":"C139","DOI":"10.1152\/ajpcell.00773.2024","volume":"328","author":"LJ Novinger","year":"2025","unstructured":"Novinger LJ, Weinzierl NM, Bonetto A. Diversity in chemotherapy-induced cachexia. Am J Physiol Cell Physiol. 2025;328:C139-47. https:\/\/doi.org\/10.1152\/ajpcell.00773.2024.","journal-title":"Am J Physiol Cell Physiol"},{"key":"3166_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092236","volume":"13","author":"ME Cazzaniga","year":"2021","unstructured":"Cazzaniga ME, Cordani N, Capici S, Cogliati V, Riva F, Cerrito MG. Metronomic chemotherapy. Cancers. 2021;13:2236. https:\/\/doi.org\/10.3390\/cancers13092236.","journal-title":"Cancers"},{"key":"3166_CR48","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3389\/fonc.2014.00076","volume":"4","author":"PS Malik","year":"2014","unstructured":"Malik PS, Raina V, Andr\u00e9 N. Metronomics as maintenance treatment in oncology: time for chemo-switch. Front Oncol. 2014;4:76. https:\/\/doi.org\/10.3389\/fonc.2014.00076.","journal-title":"Front Oncol"},{"key":"3166_CR49","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.7150\/thno.95619","volume":"14","author":"H Wu","year":"2024","unstructured":"Wu H, Zhou H, Chen L, Wang S. Metronomic chemotherapy in cancer treatment: new wine in an old bottle. Theranostics. 2024;14:3548\u201364. https:\/\/doi.org\/10.7150\/thno.95619.","journal-title":"Theranostics"},{"key":"3166_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142309","volume":"17","author":"V Razmovski-Naumovski","year":"2025","unstructured":"Razmovski-Naumovski V, Tanous A, Valaire R. What cachexia-related outcomes are measured in lung cancer chemotherapy clinical trials? Cancers. 2025;17:2309. https:\/\/doi.org\/10.3390\/cancers17142309.","journal-title":"Cancers"},{"key":"3166_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143615","volume":"13","author":"DG Campelj","year":"2021","unstructured":"Campelj DG, Goodman CA, Rybalka E. Chemotherapy-induced myopathy: the dark side of the cachexia sphere. Cancers. 2021;13:3615. https:\/\/doi.org\/10.3390\/cancers13143615.","journal-title":"Cancers"},{"key":"3166_CR52","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI9872","volume":"105","author":"D Hanahan","year":"2000","unstructured":"Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000;105:1045\u20137. https:\/\/doi.org\/10.1172\/JCI9872.","journal-title":"J Clin Invest"},{"key":"3166_CR53","unstructured":"Institut Bergoni\u00e9. Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma (METZOLIMOS). 2025 June. Report No.: NCT02517918. https:\/\/clinicaltrials.gov\/study\/NCT02517918#publications"},{"key":"3166_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24670","volume":"10","author":"N Jan","year":"2024","unstructured":"Jan N, Sofi S, Qayoom H, Shabir A, Haq BU, Macha MA. Metronomic chemotherapy and drug repurposing: a paradigm shift in oncology. Heliyon. 2024;10:e24670. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24670.","journal-title":"Heliyon"},{"key":"3166_CR55","unstructured":"Dana-Farber Cancer Institute. Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer (ABCDE). 2022 Jan. Report No.: NCT00925652. https:\/\/clinicaltrials.gov\/study\/NCT00925652"},{"key":"3166_CR56","unstructured":"Emory University. Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (AflacST1903). 2024 Nov. Report No.: NCT04469530. https:\/\/clinicaltrials.gov\/study\/NCT04469530"},{"key":"3166_CR57","doi-asserted-by":"crossref","unstructured":"Alves CRR, Melo CM, de Almeida NR, Chammas R, Brum PC. Metronomic chemotherapy with cisplatin induces skeletal muscle wasting and impairs Ubiquitin-Proteasome system in B16-F10 Tumor-Bearing mice. 2017. https:\/\/www.jscimedcentral.com\/public\/assets\/articles\/musclehealth-1-1006.pdf","DOI":"10.1002\/j.2617-1619.2018.tb00008.x"},{"issue":"5","key":"3166_CR58","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1593\/tlo.13481","volume":"6","author":"T Torimura","year":"2013","unstructured":"Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Transl Oncol. 2013;6(5):511\u20139. https:\/\/doi.org\/10.1593\/tlo.13481.","journal-title":"Transl Oncol"},{"key":"3166_CR59","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3747\/co.v16i2.420","volume":"16","author":"OG Scharovsky","year":"2009","unstructured":"Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol Tor Ont. 2009;16:7\u201315. https:\/\/doi.org\/10.3747\/co.v16i2.420.","journal-title":"Curr Oncol Tor Ont"},{"key":"3166_CR60","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1631\/jzus.B1800171","volume":"20","author":"B Park","year":"2019","unstructured":"Park B, You S, Cho WCS, Choi J-Y, Lee MS. A systematic review of herbal medicines for the treatment of cancer cachexia in animal models. J Zhejiang Univ Sci B. 2019;20:9\u201322. https:\/\/doi.org\/10.1631\/jzus.B1800171.","journal-title":"J Zhejiang Univ Sci B"},{"key":"3166_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/ph14111084","volume":"14","author":"JMO Santos","year":"2021","unstructured":"Santos JMO, Costa AC, Dias TR, Satari S, Costa E Silva MP, Da Costa RMG, et al. Towards drug repurposing in cancer cachexia: potential targets and candidates. Pharmaceuticals. 2021;14:1084. https:\/\/doi.org\/10.3390\/ph14111084.","journal-title":"Pharmaceuticals"},{"key":"3166_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4103\/picr.picr_70_24","volume":"16","author":"K Saranraj","year":"2025","unstructured":"Saranraj K, Kiran PU. Drug repurposing: clinical practices and regulatory pathways. Perspect Clin Res. 2025;16:61\u20138. https:\/\/doi.org\/10.4103\/picr.picr_70_24.","journal-title":"Perspect Clin Res"},{"key":"3166_CR63","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.11526","volume":"40","author":"M Toulmonde","year":"2022","unstructured":"Toulmonde M, Marec-Berard P, Lervat C, Cantarel C, Toulza E, Sellan-Albert S, et al. Metzolimos metronomic cyclophosphamide (CP) and methotrexate (MTX) combined with zoledronic acid (ZA) and sirolimus (SIR) in patients with advanced solid tumor with bone metastasis and advanced pretreated osteosarcoma (OSS): a phase Ib study. J Clin Oncol. 2022;40:11526. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.11526.","journal-title":"J Clin Oncol"},{"key":"3166_CR64","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.3390\/cancers15123199","volume":"15","author":"MA Hijazi","year":"2023","unstructured":"Hijazi MA, Gessner A, El-Najjar N. Repurposing of chronically used drugs in cancer therapy: a chance to grasp. Cancers. 2023;15:3199. https:\/\/doi.org\/10.3390\/cancers15123199.","journal-title":"Cancers"},{"key":"3166_CR65","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171:1437-1452.e17. https:\/\/doi.org\/10.1016\/j.cell.2017.10.049.","journal-title":"Cell"},{"key":"3166_CR66","doi-asserted-by":"publisher","first-page":"D1265","DOI":"10.1093\/nar\/gkad976","volume":"52","author":"C Knox","year":"2024","unstructured":"Knox C, Wilson M, Klinger CM, Franklin M, Oler E, Wilson A, et al. DrugBank 6.0: The DrugBank Knowledgebase for 2024. Nucleic Acids Res. 2024;52:D1265-75. https:\/\/doi.org\/10.1093\/nar\/gkad976.","journal-title":"Nucleic Acids Res"},{"key":"3166_CR67","doi-asserted-by":"publisher","unstructured":"Pi\u00f1ero J, Ram\u00edrez-Anguita JM, Sa\u00fcch-Pitarch J, Ronzano F, Centeno E, Sanz F, et al. The disgenet knowledge platform for disease genomics: 2019 update. Nucleic Acids Res 2019;gkz1021. https:\/\/doi.org\/10.1093\/nar\/gkz1021.","DOI":"10.1093\/nar\/gkz1021"},{"key":"3166_CR68","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1056\/NEJMsa1012065","volume":"364","author":"DA Zarin","year":"2011","unstructured":"Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database \u2014 update and key issues. N Engl J Med. 2011;364:852\u201360. https:\/\/doi.org\/10.1056\/NEJMsa1012065.","journal-title":"N Engl J Med"},{"key":"3166_CR69","doi-asserted-by":"publisher","first-page":"D1075","DOI":"10.1093\/nar\/gkv1075","volume":"44","author":"M Kuhn","year":"2016","unstructured":"Kuhn M, Letunic I, Jensen LJ, Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016;44:D1075-9. https:\/\/doi.org\/10.1093\/nar\/gkv1075.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"3166_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-021-04076-w","volume":"22","author":"G Fiscon","year":"2021","unstructured":"Fiscon G, Paci P. SAveRUNNER: an R-based tool for drug repurposing. BMC Bioinformatics. 2021;22(1):150. https:\/\/doi.org\/10.1186\/s12859-021-04076-w.","journal-title":"BMC Bioinformatics"},{"key":"3166_CR71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/pro.3978","volume":"30","author":"R Oughtred","year":"2021","unstructured":"Oughtred R, Rust J, Chang C, Breitkreutz B-J, Stark C, Willems A, et al. The BioGRID database: a comprehensive biomedical resource of curated protein, genetic, and chemical interactions. Protein Sci. 2021;30:187\u2013200. https:\/\/doi.org\/10.1002\/pro.3978.","journal-title":"Protein Sci"},{"issue":"1","key":"3166_CR72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168.","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"3166_CR73","doi-asserted-by":"publisher","first-page":"10001","DOI":"10.1021\/acs.chemrev.5c00461","volume":"125","author":"O Zhang","year":"2025","unstructured":"Zhang O, Lin H, Zhang X, Wang X, Wu Z, Ye Q, et al. Graph Neural Networks in Modern AI-aided Drug Discovery. Chem Rev. 2025;125(20):10001\u2013103. https:\/\/doi.org\/10.1021\/acs.chemrev.5c00461.","journal-title":"Chem Rev"},{"key":"3166_CR74","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1124\/pharmrev.122.000715","volume":"75","author":"D Trajanov","year":"2023","unstructured":"Trajanov D, Trajkovski V, Dimitrieva M, Dobreva J, Jovanovik M, Klemen M, et al. Review of Natural Language Processing in Pharmacology. Pharmacol Rev. 2023;75:714\u201338. https:\/\/doi.org\/10.1124\/pharmrev.122.000715.","journal-title":"Pharmacol Rev"},{"key":"3166_CR75","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1002\/mco2.164","volume":"3","author":"Y-F Wang","year":"2022","unstructured":"Wang Y-F, An Z-Y, Lin D-H, Jin W-L. Targeting cancer cachexia: molecular mechanisms and clinical study. MedComm. 2022;3:e164. https:\/\/doi.org\/10.1002\/mco2.164.","journal-title":"MedComm"},{"key":"3166_CR76","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.tem.2021.03.007","volume":"32","author":"T Siff","year":"2021","unstructured":"Siff T, Parajuli P, Razzaque MS, Atfi A. Cancer-mediated muscle cachexia: etiology and clinical management. Trends Endocrinol Metab TEM. 2021;32:382\u2013402. https:\/\/doi.org\/10.1016\/j.tem.2021.03.007.","journal-title":"Trends Endocrinol Metab TEM"},{"key":"3166_CR77","doi-asserted-by":"publisher","first-page":"C1837","DOI":"10.1152\/ajpcell.00808.2024","volume":"328","author":"N Iaia","year":"2025","unstructured":"Iaia N, Noviello C, Muscaritoli M, Costelli P. Inflammation in cancer cachexia: still the central tenet or just another player? Am J Physiol-Cell Physiol. 2025;328:C1837-52. https:\/\/doi.org\/10.1152\/ajpcell.00808.2024.","journal-title":"Am J Physiol-Cell Physiol"},{"key":"3166_CR78","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","volume":"170","author":"HJ Patel","year":"2017","unstructured":"Patel HJ, Patel BM. TNF-\u03b1 and cancer cachexia: molecular insights and clinical implications. Life Sci. 2017;170:56\u201363. https:\/\/doi.org\/10.1016\/j.lfs.2016.11.033.","journal-title":"Life Sci"},{"key":"3166_CR79","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1186\/ar4615","volume":"16","author":"C Zamora-Atenza","year":"2014","unstructured":"Zamora-Atenza C, Diaz-Torne C, Geli C, Diaz-Lopez C, Ortiz MA, Moya P, et al. Adalimumab regulates intracellular TNF\u03b1 production in patients with rheumatoid arthritis. Arthritis Res Ther. 2014;16:R153. https:\/\/doi.org\/10.1186\/ar4615.","journal-title":"Arthritis Res Ther"},{"key":"3166_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110434","volume":"146","author":"M Kiedrowski","year":"2021","unstructured":"Kiedrowski M, Kapala P, Kiedrowska M, Skoczynska A, Czerw A, Depta\u0142a A. Can chloroquine\/hydroxychloroquine prove efficient in cancer cachexia? A hypothesis in the era of COVID-19. Med Hypotheses. 2021;146:110434. https:\/\/doi.org\/10.1016\/j.mehy.2020.110434.","journal-title":"Med Hypotheses"},{"issue":"3","key":"3166_CR81","doi-asserted-by":"publisher","first-page":"192","DOI":"10.2174\/187221411797265890","volume":"5","author":"P Bodera","year":"2011","unstructured":"Bodera P, Stankiewicz W. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications. Recent Pat Endocr Metab Immune Drug Discov. 2011;5(3):192\u20136. https:\/\/doi.org\/10.2174\/187221411797265890.","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"3166_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116304","volume":"173","author":"Q Guo","year":"2024","unstructured":"Guo Q, Zhao M, Wang Q, Lu T, Luo P, Chen L, et al. Glycyrrhetinic acid inhibits non-small cell lung cancer via promotion of Prdx6- and caspase-3-mediated mitochondrial apoptosis. Biomed Pharmacother. 2024;173:116304. https:\/\/doi.org\/10.1016\/j.biopha.2024.116304.","journal-title":"Biomed Pharmacother"},{"key":"3166_CR83","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","volume":"8","author":"AA Narsale","year":"2014","unstructured":"Narsale AA, Carson JA. Role of interleukin-6 in cachexia: therapeutic implications. Curr Opin Support Palliat Care. 2014;8:321\u20137. https:\/\/doi.org\/10.1097\/SPC.0000000000000091.","journal-title":"Curr Opin Support Palliat Care"},{"key":"3166_CR84","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73:1616\u201325. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205137.","journal-title":"Ann Rheum Dis"},{"key":"3166_CR85","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2147\/DDDT.S115456","volume":"11","author":"R R\u00edos-Tamayo","year":"2017","unstructured":"R\u00edos-Tamayo R, Mart\u00edn-Garc\u00eda A, Alarc\u00f3n-Payer C, S\u00e1nchez-Rodr\u00edguez D, de la Guardia AMDVD, Garc\u00eda Collado CG, et al. Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy. Drug Des Devel Ther. 2017;11:2399\u2013408. https:\/\/doi.org\/10.2147\/DDDT.S115456.","journal-title":"Drug Des Devel Ther"},{"key":"3166_CR86","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1002\/jcsm.13638","volume":"15","author":"Y Du","year":"2024","unstructured":"Du Y, Liu X-Y, Pan R-L, Zhang X-T, Si X-Y, Chen M-J, et al. Tocilizumab for advanced non-small-cell lung cancer with concomitant cachexia: an observational study. J Cachexia Sarcopenia Muscle. 2024;15:2815\u201325. https:\/\/doi.org\/10.1002\/jcsm.13638.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3166_CR87","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10753-021-01429-8","volume":"44","author":"BJ Laird","year":"2021","unstructured":"Laird BJ, McMillan D, Skipworth RJE, Fallon MT, Paval DR, McNeish I, et al. The emerging role of interleukin 1\u03b2 (IL-1\u03b2) in cancer cachexia. Inflammation. 2021;44:1223\u20138. https:\/\/doi.org\/10.1007\/s10753-021-01429-8.","journal-title":"Inflammation"},{"issue":"3","key":"3166_CR88","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.amjmed.2018.10.013","volume":"132","author":"A Dhorepatil","year":"2019","unstructured":"Dhorepatil A, Ball S, Ghosh RK, Kondapaneni M, Lavie CJ. Canakinumab: promises and future in cardiometabolic diseases and malignancy. Am J Med. 2019;132(3):312\u201324. https:\/\/doi.org\/10.1016\/j.amjmed.2018.10.013.","journal-title":"Am J Med"},{"key":"3166_CR89","first-page":"138","volume":"34","author":"S Kapur","year":"2009","unstructured":"Kapur S, Bonk ME. Rilonacept (arcalyst), an interleukin-1 trap for the treatment of cryopyrin-associated periodic syndromes. P T Peer-Rev J Formul Manag. 2009;34:138\u201341.","journal-title":"P T Peer-Rev J Formul Manag"},{"key":"3166_CR90","first-page":"3959","volume":"30","author":"U Harnack","year":"2010","unstructured":"Harnack U, Johnen H, Pecher G. IL-1 receptor antagonist Anakinra enhances tumour growth inhibition in mice receiving peptide vaccination and beta-(1\u20133),(1\u20136)-D-glucan. Anticancer Res. 2010;30:3959\u201365.","journal-title":"Anticancer Res"},{"issue":"2","key":"3166_CR91","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clnu.2011.10.005","volume":"31","author":"C Madeddu","year":"2012","unstructured":"Madeddu C, Dess\u00ec M, Panzone F, Serpe R, Antoni G, Cau MC, et al. Randomized phase III clinical trial of a combined treatment with carnitine\u2009+\u2009celecoxib\u2009\u00b1\u2009megestrol acetate for patients with cancer-related anorexia\/cachexia syndrome. Clin Nutr. 2012;31(2):176\u201382. https:\/\/doi.org\/10.1016\/j.clnu.2011.10.005.","journal-title":"Clin Nutr"},{"key":"3166_CR92","doi-asserted-by":"publisher","first-page":"5262","DOI":"10.3390\/cancers14215262","volume":"14","author":"G Clamon","year":"2022","unstructured":"Clamon G, Byrne MM, Talbert EE. Inflammation as a therapeutic target in cancer cachexia. Cancers. 2022;14:5262. https:\/\/doi.org\/10.3390\/cancers14215262.","journal-title":"Cancers"},{"key":"3166_CR93","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/sj.bjc.6690077","volume":"79","author":"DC McMillan","year":"1999","unstructured":"McMillan DC, Wigmore SJ, Wigmore KCH, O\u2019Gorman P, Wright CE, McArdle CS. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Br J Cancer. 1999;79:495\u2013500. https:\/\/doi.org\/10.1038\/sj.bjc.6690077.","journal-title":"Br J Cancer"},{"key":"3166_CR94","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/iep.12383","volume":"102","author":"MLJ Micheletto","year":"2021","unstructured":"Micheletto MLJ, Hermes TdeA, Bertassoli BM, Petri G, Perez MM, Fonseca FLA, et al. Ixazomib, an oral proteasome inhibitor, exhibits potential effect in dystrophin-deficient mdx mice. Int J Exp Pathol. 2021;102:11\u201321. https:\/\/doi.org\/10.1111\/iep.12383.","journal-title":"Int J Exp Pathol"},{"key":"3166_CR95","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s11864-010-0127-z","volume":"11","author":"NB Kumar","year":"2010","unstructured":"Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol. 2010;11:107\u201317. https:\/\/doi.org\/10.1007\/s11864-010-0127-z.","journal-title":"Curr Treat Options Oncol"},{"key":"3166_CR96","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay9592","volume":"13","author":"R Sartori","year":"2021","unstructured":"Sartori R, Hagg A, Zampieri S, Armani A, Winbanks CE, Viana LR, et al. Perturbed BMP signaling and denervation promote muscle wasting in cancer cachexia. Sci Transl Med. 2021;13:eaay9592. https:\/\/doi.org\/10.1126\/scitranslmed.aay9592.","journal-title":"Sci Transl Med"},{"key":"3166_CR97","doi-asserted-by":"publisher","DOI":"10.3390\/ph13080194","volume":"13","author":"M Sztiller-Sikorska","year":"2020","unstructured":"Sztiller-Sikorska M, Czyz M. Parthenolide as cooperating agent for anti-cancer treatment of various malignancies. Pharmaceuticals. 2020;13:194. https:\/\/doi.org\/10.3390\/ph13080194.","journal-title":"Pharmaceuticals"},{"key":"3166_CR98","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ddr.21565","volume":"80","author":"JMO Santos","year":"2019","unstructured":"Santos JMO, Moreira-Pais A, Neto T, Peixoto Da Silva S, Oliveira PA, Ferreira R, et al. Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16\u2010transgenic mice. Drug Dev Res 2019;80:824\u201330. https:\/\/doi.org\/10.1002\/ddr.21565.","journal-title":"Drug Dev Res\u00a0"},{"issue":"1","key":"3166_CR99","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3109\/0284186X.2012.724536","volume":"52","author":"TS Solheim","year":"2013","unstructured":"Solheim TS, Fearon KCH, Blum D, Kaasa S. Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol. 2013;52(1):6\u201317. https:\/\/doi.org\/10.3109\/0284186X.2012.724536.","journal-title":"Acta Oncol"},{"issue":"1","key":"3166_CR100","doi-asserted-by":"publisher","DOI":"10.1186\/s40170-021-00249-6","volume":"9","author":"M Thanee","year":"2021","unstructured":"Thanee M, Padthaisong S, Suksawat M, Dokduang H, Phetcharaburanin J, Klanrit P, et al. Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models. Cancer Metab. 2021;9(1):11. https:\/\/doi.org\/10.1186\/s40170-021-00249-6.","journal-title":"Cancer Metab"},{"issue":"4","key":"3166_CR101","doi-asserted-by":"publisher","first-page":"1143S","DOI":"10.3945\/ajcn.2010.28608E","volume":"91","author":"NP Gullett","year":"2010","unstructured":"Gullett NP, Hebbar G, Ziegler TR. Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting. Am J Clin Nutr. 2010;91(4):1143S-1147S. https:\/\/doi.org\/10.3945\/ajcn.2010.28608E.","journal-title":"Am J Clin Nutr"},{"key":"3166_CR102","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(13)70055-X","volume":"14","author":"AS Dobs","year":"2013","unstructured":"Dobs AS, Boccia RV, Croot CC, Gabrail NY, Dalton JT, Hancock ML, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14:335\u201345. https:\/\/doi.org\/10.1016\/S1470-2045(13)70055-X.","journal-title":"Lancet Oncol"},{"key":"3166_CR103","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/sj.bjc.6602165","volume":"91","author":"SM Wyke","year":"2004","unstructured":"Wyke SM, Russell ST, Tisdale MJ. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-\u03baB activation. Br J Cancer. 2004;91:1742\u201350. https:\/\/doi.org\/10.1038\/sj.bjc.6602165.","journal-title":"Br J Cancer"},{"key":"3166_CR104","doi-asserted-by":"publisher","DOI":"10.4103\/abr.abr_366_21","volume":"11","author":"A Hosseini Dastgerdi","year":"2022","unstructured":"Hosseini Dastgerdi A, Ghanbari Rad M, Soltani N. The therapeutic effects of magnesium in insulin secretion and insulin resistance. Adv Biomed Res. 2022;11:54. https:\/\/doi.org\/10.4103\/abr.abr_366_21.","journal-title":"Adv Biomed Res"},{"key":"3166_CR105","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1007\/s00520-016-3144-z","volume":"24","author":"K Takayama","year":"2016","unstructured":"Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer. 2016;24:3495\u2013505. https:\/\/doi.org\/10.1007\/s00520-016-3144-z.","journal-title":"Support Care Cancer"},{"key":"3166_CR106","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3892\/ol.2023.14049","volume":"26","author":"T Ling","year":"2023","unstructured":"Ling T, Zhang J, Ding F, Ma L. Role of growth differentiation factor 15 in cancer cachexia (Review). Oncol Lett. 2023;26:462. https:\/\/doi.org\/10.3892\/ol.2023.14049.","journal-title":"Oncol Lett"},{"key":"3166_CR107","unstructured":"University of Edinburgh. Muscle Wasting in Cancer (MWIC). 2025 June. Report No.: NCT03191955. https:\/\/clinicaltrials.gov\/study\/NCT03191955#publications"},{"key":"3166_CR108","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","volume":"391","author":"JD Groarke","year":"2024","unstructured":"Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, et al. Ponsegromab for the treatment of cancer cachexia. N Engl J Med. 2024;391:2291\u2013303. https:\/\/doi.org\/10.1056\/NEJMoa2409515.","journal-title":"N Engl J Med"},{"key":"3166_CR109","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/biology10080700","volume":"10","author":"SV Chitti","year":"2021","unstructured":"Chitti SV, Marzan AL, Shahi S, Kang T, Fonseka P, Mathivanan S. Repurposing of antibiotic sulfisoxazole inhibits lipolysis in pre-clinical model of cancer-associated cachexia. Biol. 2021;10:700. https:\/\/doi.org\/10.3390\/biology10080700.","journal-title":"Biol"},{"key":"3166_CR110","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","volume":"20","author":"M Petruzzelli","year":"2014","unstructured":"Petruzzelli M, Schweiger M, Schreiber R, Campos-Olivas R, Tsoli M, Allen J, et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 2014;20:433\u201347. https:\/\/doi.org\/10.1016\/j.cmet.2014.06.011.","journal-title":"Cell Metab"},{"issue":"14","key":"3166_CR111","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1200\/JCO.22.01997","volume":"41","author":"L Sandhya","year":"2023","unstructured":"Sandhya L, Devi Sreenivasan N, Goenka L, Dubashi B, Kayal S, Solaiappan M, et al. Randomized double-blind placebo-controlled study of olanzapine for chemotherapy-related anorexia in patients with locally advanced or metastatic gastric, hepatopancreaticobiliary, and lung cancer. J Clin Oncol. 2023;41(14):2617\u201327. https:\/\/doi.org\/10.1200\/JCO.22.01997.","journal-title":"J Clin Oncol"},{"key":"3166_CR112","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/jcsm.13249","volume":"14","author":"J Springer","year":"2023","unstructured":"Springer J, Jov\u00e9 Q, De Lima Junior EA, Ladr\u00f3n N\u00c1, L\u00f3pez-Soriano FJ, Busquets S, et al. Effects of S\u2010pindolol in mouse pancreatic and lung cancer cachexia models. J Cachexia Sarcopenia Muscle. 2023;14:1244\u20138. https:\/\/doi.org\/10.1002\/jcsm.13249.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"3166_CR113","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13651","volume":"16","author":"F Misselwitz","year":"2025","unstructured":"Misselwitz F, Henderson D, Menakuru SR, Morten E, Roe C, Whitaker G, et al. Pharmacokinetics, pharmacodynamics and bioavailability of ACM-001.1 ( S \u2010pindolol benzoate) in healthy volunteers. J Cachexia Sarcopenia Muscle. 2025;16(1):e13651. https:\/\/doi.org\/10.1002\/jcsm.13651.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3166_CR114","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.autneu.2011.09.006","volume":"166","author":"A Chauhan","year":"2012","unstructured":"Chauhan A, Sequeria A, Manderson C, Maddocks M, Wasley D, Wilcock A. Exploring autonomic nervous system dysfunction in patients with cancer cachexia: a pilot study. Auton Neurosci. 2012;166:93\u20135. https:\/\/doi.org\/10.1016\/j.autneu.2011.09.006.","journal-title":"Auton Neurosci"},{"issue":"1","key":"3166_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2424-9","volume":"16","author":"AG Oliveira","year":"2016","unstructured":"Oliveira AG, Gomes-Marcondes MCC. Metformin treatment modulates the tumour-induced wasting effects in muscle protein metabolism minimising the cachexia in tumour-bearing rats. BMC Cancer. 2016;16(1):418. https:\/\/doi.org\/10.1186\/s12885-016-2424-9.","journal-title":"BMC Cancer"},{"key":"3166_CR116","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.ijcard.2013.04.150","volume":"168","author":"S Palus","year":"2013","unstructured":"Palus S, Von Haehling S, Flach VC, Tschirner A, Doehner W, Anker SD, et al. Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. Int J Cardiol. 2013;168:3412\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2013.04.150.","journal-title":"Int J Cardiol"},{"issue":"1","key":"3166_CR117","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bmjspcare-2020-002601","volume":"11","author":"M Saeteaw","year":"2021","unstructured":"Saeteaw M, Sanguanboonyaphong P, Yoodee J, Craft K, Sawangjit R, Ngamphaiboon N, et al. Efficacy and safety of pharmacological cachexia interventions: systematic review and network meta-analysis. BMJ Support Palliat Care. 2021;11(1):75\u201385. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002601.","journal-title":"BMJ Support Palliat Care"},{"issue":"1","key":"3166_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82120-8","volume":"11","author":"DC Currow","year":"2021","unstructured":"Currow DC, Glare P, Louw S, Martin P, Clark K, Fazekas B, et al. A randomised, double blind, placebo-controlled trial of megestrol acetate or dexamethasone in treating symptomatic anorexia in people with advanced cancer. Sci Rep. 2021;11(1):2421. https:\/\/doi.org\/10.1038\/s41598-021-82120-8.","journal-title":"Sci Rep"},{"key":"3166_CR119","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clnesp.2023.12.150","volume":"59","author":"F Hosseini","year":"2024","unstructured":"Hosseini F, Hemmati A, Takabi FS, Naeini F, Shab Bidar S. A dose\u2013response meta-analysis of randomized clinical trials investigating the effects of omega-3 supplementation on body weight in patients with cancer cachexia. Clin Nutr ESPEN. 2024;59:378\u201386. https:\/\/doi.org\/10.1016\/j.clnesp.2023.12.150.","journal-title":"Clin Nutr ESPEN"},{"key":"3166_CR120","unstructured":"Ellipses Pharma. Phase 1\/\u200b2 study to evaluate Vosilasarm (EP0062) as monotherapy and in combination in patients with advanced or metastatic AR+\/\u200bHER-2-\/\u200bER\u2009+\u2009Breast cancer. 2025 Feb. Report No.: NCT05573126. https:\/\/clinicaltrials.gov\/study\/NCT05573126"},{"key":"3166_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112972","volume":"15","author":"I Ioakeim-Skoufa","year":"2023","unstructured":"Ioakeim-Skoufa I, Tobajas-Ramos N, Menditto E, Aza-Pascual-Salcedo M, Gimeno-Miguel A, Orlando V, et al. Drug repurposing in oncology: a systematic review of randomized controlled clinical trials. Cancers. 2023;15:2972. https:\/\/doi.org\/10.3390\/cancers15112972.","journal-title":"Cancers"},{"key":"3166_CR122","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7170","volume":"13","author":"K Takayama","year":"2024","unstructured":"Takayama K, Kojima A, Honda C, Nakayama M, Kanemata S, Endo T, et al. Real-world safety and effectiveness of anamorelin for cancer cachexia: interim analysis of post\u2010marketing surveillance in Japan. Cancer Med. 2024;13:e7170. https:\/\/doi.org\/10.1002\/cam4.7170.","journal-title":"Cancer Med"},{"key":"3166_CR123","unstructured":"Norwegian University of Science and Technology. Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy (MENAC). 2024 June. Report No.: NCT02330926. https:\/\/clinicaltrials.gov\/study\/NCT02330926"},{"issue":"4","key":"3166_CR124","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0538-6","volume":"32","author":"Q Wang","year":"2015","unstructured":"Wang Q, Li C, Peng X, Kang Q, Deng D, Zhang L, et al. Combined treatment of carfilzomib and z-VAD-fmk inhibits skeletal proteolysis and apoptosis and ameliorates cancer cachexia. Med Oncol. 2015;32(4):100. https:\/\/doi.org\/10.1007\/s12032-015-0538-6.","journal-title":"Med Oncol"},{"key":"3166_CR125","doi-asserted-by":"publisher","DOI":"10.1177\/1534735420940414","volume":"19","author":"T Niels","year":"2020","unstructured":"Niels T, Tomanek A, Freitag N, Schumann M. Can exercise counteract cancer cachexia? A systematic literature review and meta-analysis. Integr Cancer Ther. 2020;19:1534735420940414. https:\/\/doi.org\/10.1177\/1534735420940414.","journal-title":"Integr Cancer Ther"},{"key":"3166_CR126","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84538-6","volume":"11","author":"A Schcolnik-Cabrera","year":"2021","unstructured":"Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, Juarez M, Vargas-Castillo A, Ponce-Toledo RI, et al. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy. Sci Rep. 2021;11:5222. https:\/\/doi.org\/10.1038\/s41598-021-84538-6.","journal-title":"Sci Rep"},{"issue":"1","key":"3166_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84538-6","volume":"11","author":"A Schcolnik-Cabrera","year":"2021","unstructured":"Schcolnik-Cabrera A, Chavez-Blanco A, Dominguez-Gomez G, Juarez M, Vargas-Castillo A, Ponce-Toledo RI, et al. Pharmacological inhibition of tumor anabolism and host catabolism as a cancer therapy. Sci Rep. 2021;11(1):5222. https:\/\/doi.org\/10.1038\/s41598-021-84538-6.","journal-title":"Sci Rep"},{"issue":"1","key":"3166_CR128","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2005.07.026","volume":"42","author":"M Muscaritoli","year":"2006","unstructured":"Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F. Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006;42(1):31\u201341. https:\/\/doi.org\/10.1016\/j.ejca.2005.07.026.","journal-title":"Eur J Cancer"},{"issue":"2","key":"3166_CR129","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1017\/S0029665199000439","volume":"58","author":"J Congleton","year":"1999","unstructured":"Congleton J. The pulmonary cachexia syndrome: aspects of energy balance. Proc Nutr Soc. 1999;58(2):321\u20138. https:\/\/doi.org\/10.1017\/S0029665199000439.","journal-title":"Proc Nutr Soc"},{"key":"3166_CR130","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.critrevonc.2013.07.001","volume":"88","author":"GB Stene","year":"2013","unstructured":"Stene GB, Helbostad JL, Balstad TR, Riphagen II, Kaasa S, Oldervoll LM. Effect of physical exercise on muscle mass and strength in cancer patients during treatment\u2014a systematic review. Crit Rev Oncol Hematol. 2013;88:573\u201393. https:\/\/doi.org\/10.1016\/j.critrevonc.2013.07.001.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3166_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1600425","volume":"15","author":"E Oneda","year":"2025","unstructured":"Oneda E, Manno A, Noventa S, Libertini M, Cherri S, Zaniboni A. Role of diet, physical activity and new drugs in the primary management of cancer cachexia in gastrointestinal tumors - a comprehensive review. Front Oncol. 2025;15:1600425. https:\/\/doi.org\/10.3389\/fonc.2025.1600425.","journal-title":"Front Oncol"},{"issue":"5","key":"3166_CR132","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103245","volume":"9","author":"JM Shin","year":"2022","unstructured":"Shin JM, Lee C, Son S, Kim CH, Lee JA, Ko H, et al. Sulfisoxazole elicits robust antitumour immune response along with immune checkpoint therapy by inhibiting exosomal PD-L1. Adv Sci. 2022;9(5):2103245. https:\/\/doi.org\/10.1002\/advs.202103245.","journal-title":"Adv Sci"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03166-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03166-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03166-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T03:49:57Z","timestamp":1769485797000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03166-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":132,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3166"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03166-6","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"As this is a review study and did not use preclinical or clinical-level data, no Ethics Committee approval is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All the authors declare that no generative AI or AI-assisted technologies have been utilized while drafting this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration for use of generative AI or AI-assisted technologies"}}],"article-number":"40"}}